Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism
NCT02604238 · Azienda U.S.L. 1 di Massa e Carrara · PHASE3 · withdrawn · last registry update 2024-02-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Azienda U.S.L. 1 di Massa e Carrara |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLAT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-31Results posted on the registry: University of Calgary, Tenecteplase + Antiplatelet treatment (NCT02398656)
- 2025-01-15Also stopped (terminated): University of Melbourne, Tenecteplase + Standard Care (which may include intravenous Alteplase) (NCT04454788)
- 2025-01-10Phase 3 first posted: Central Hospital, Nancy, France, Intra-arterial infusion of Alteplase (NCT06768138)
- 2024-12-27Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Intravenous thrombolysis (NCT06749834)
- 2024-12-11Results posted on the registry: Memorial Healthcare System, Cathflo Activase + Talc Slurry Pleurodesis (NCT04806373)
- 2024-12-10Results posted on the registry: Boehringer Ingelheim, tenecteplase + alteplase (NCT04915729)
- 2024-10-28Phase 3 first posted: Shin Poong Pharmaceutical Co. Ltd., SP-8203 + Placebo (NCT06660719)
- 2024-10-26Phase 3 first posted: Xuanwu Hospital, Beijing, Tenecteplase + Alteplase (NCT06658197)
- 2024-10-22Results posted on the registry: Wake Forest University Health Sciences, Tranexamic acid + Epsilon Aminocaproic Acid (NCT02656472)
- 2024-10-16Also stopped (withdrawn): Wake Forest University Health Sciences, Tenecteplase (NCT00431379)
- 2024-10-04Results posted on the registry: KU Leuven, Tenecteplase + Clopidogrel (NCT02777580)
- 2024-10-01Also stopped (withdrawn): ZZ Biotech, LLC, 3K3A-APC (NCT05484154)
- 2024-09-19Also stopped (suspended): Centre hospitalier de l'Université de Montréal (CHUM), Best standard treatment (NCT02157532)
- 2024-08-23Results posted on the registry: Chiesi Farmaceutici S.p.A., CUSA-081 + Placebo (NCT03594175)
- 2024-08-23Also stopped (terminated): Chiesi Farmaceutici S.p.A., CUSA-081 + Placebo (NCT03594175)
- 2024-06-26Results posted on the registry: NYU Langone Health, Tranexamic acid + Aminocaproic acid (NCT04814433)
- 2024-06-26Also stopped (terminated): NYU Langone Health, Tranexamic acid + Aminocaproic acid (NCT04814433)
- 2024-06-12Phase 3 first posted: Jesper Kjaergaard, Heparin (NCT06453876)
- 2024-05-22Results posted on the registry: Genentech, Inc., Tenecteplase (NCT03785678)
- 2024-04-09Also stopped (withdrawn): Zeenat Qureshi Stroke Institute, Reteplase Injection (NCT05900674)
- 2024-04-08Phase 3 first posted: The George Institute, Standard-dose intravenous tenecteplase + Low-dose intravenous tenecteplase (NCT06352632)
- 2024-03-20Phase 3 first posted: University of Calgary, Tenecteplase (NCT06320431)
- 2024-03-07Results posted on the registry: Boehringer Ingelheim, Alteplase low dose + Alteplase high dose (NCT04640194)
- 2024-02-20Results posted on the registry: University of Florida, tPA + DNase (NCT03213834)
- 2024-01-24Phase 3 first posted: Beijing Tiantan Hospital, Tenecteplase (NCT06221371)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision